Amin N'Cho Christophe, Fabre Huguette, Blanchin Marie-Dominique, Montels Jérôme, Aké Michèle
Malar J. 2013 Jun 13;12:202. doi: 10.1186/1475-2875-12-202.
Artemether-lumefantrine (AL) combination therapy is now the most used anti-malarial treatment in the world. Quality control of AL formulations is still a major challenge in developing countries. Until now, only liquid chromatographic methods have been reported in the literature for their analysis. Capillary electrophoretic methods, which present various advantages (low price of capillary, low volumes of electrolyte consumption), may be an alternative to liquid chromatography methods. In this paper, a reliable method was developed and validated for the determination of AL in commercial fixed-dose combination tablets commercialized in Côte d'Ivoire.
Artemether and lumefantrine were determined by microemulsion electrokinetic chromatography using short-end injection procedure. The two analytes were extracted from tablets by acidified methanol. Pyrimethamine was used as internal standard. Separation was carried out in an uncoated fused silica capillary, 30 cm long × 50 μm internal diameter, using an effective length of 10 cm and a microemulsion composed of octane, butanol, sodium dodecyl sulfate and borate buffer as background electrolyte, a - 500 V x cm(-1) electric field and a detection wavelength of 214 nm.
Artemether, lumefantrine and pyrimethamine were separated in 6 min. The method was reliable with respect to selectivity towards formulation excipients, linearity of the response function (r2 > 0.998), recovery studies from synthetic tablets (in the range 99-101%), repeatability (relative standard deviation 1-3%, n = 7 analytical procedures). Application to four commercial formulations containing 20/120 mg of AL per tablet gave a content in good agreement with the declared content. However, the electropherogram of one tablet formulation showed the presence of an ingredient which was not declared.
The developed MEEKC method can be proposed as an alternative method to liquid chromatography for the determination of artemether and lumefantrine in fixed-dose combination tablet formulations.
蒿甲醚-本芴醇(AL)联合疗法是目前世界上使用最广泛的抗疟治疗方法。在发展中国家,AL制剂的质量控制仍然是一项重大挑战。到目前为止,文献中仅报道了用于其分析的液相色谱法。具有各种优点(毛细管价格低、电解质消耗体积小)的毛细管电泳法可能是液相色谱法的一种替代方法。本文建立并验证了一种可靠的方法,用于测定在科特迪瓦商业化的固定剂量复方片剂中的AL。
采用短端进样程序,通过微乳液电动色谱法测定蒿甲醚和本芴醇。两种分析物用酸化甲醇从片剂中提取。乙胺嘧啶用作内标。在一根未涂层熔融石英毛细管中进行分离,毛细管长30 cm×内径50μm,有效长度为10 cm,以由辛烷、丁醇、十二烷基硫酸钠和硼酸盐缓冲液组成的微乳液作为背景电解质,电场强度为-500 V·cm⁻¹,检测波长为214 nm。
蒿甲醚、本芴醇和乙胺嘧啶在6分钟内分离。该方法在对制剂辅料的选择性、响应函数的线性(r²>0.998)、合成片剂的回收率研究(范围为99 - 101%)、重复性(相对标准偏差1 - 3%,n = 7次分析程序)方面是可靠的。应用于四种每片含20/120 mg AL的商业制剂,其含量与申报含量高度一致。然而,一种片剂制剂的电泳图显示存在一种未申报的成分。
所建立的微乳液电动色谱法可作为液相色谱法的替代方法,用于测定固定剂量复方片剂制剂中的蒿甲醚和本芴醇。